Integrated analysis of safety and efficacy of a plasma- and albumin-free recombinant factor VIII (rAHF-PFM) from six clinical studies in patients with hemophilia A

Bibliography

• Shapiro AD, Donfield SM, Lynn HS, et al. Defining the impact of hemophilia: the Academic Achievement in Children with Hemophilia Study. Pediatrics 2001;108:E105, DOI:10.1542/peds.108.6.e105
   PubMed Web of Science ®Google Scholar
• Dargaud Y, Négrier C. Haemophilia therapies. Expert Opin Biol Ther 2007;7:651-63
   PubMed Web of Science ®Google Scholar
• Aronstam A, Arblaster PG, Rainsford SG, et al. Prophylaxis in haemophilia: a double-blind controlled trial. Br J Haematol 1976;33:81-90
   PubMed Web of Science ®Google Scholar
• Aronstam A, Kirk PJ, McHardy J, et al. Twice weekly prophylactic therapy in haemophilia A. J Clin Pathol 1977;30:65-7
   PubMed Web of Science ®Google Scholar
• Löfqvist T, Nilsson IM, Berntorp E, Pettersson H. Haemophilia prophylaxis in young patients–a long-term follow-up. J Intern Med 1997;241:395-400
   PubMed Web of Science ®Google Scholar
• Aledort LM, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group. J Intern Med 1994;236:391-9
   PubMed Web of Science ®Google Scholar
• Fischer K, van der Bom JG, Molho P, et al. Prophylactic versus on-demand treatment strategies for severe haemophilia: a comparison of costs and long-term outcome. Haemophilia 2002;8:745-52
   PubMed Web of Science ®Google Scholar
• Gringeri A. Prospective controlled studies on prophylaxis: an Italian approach. Haemophilia 2003;9(Suppl 1):38-43
   PubMed Web of Science ®Google Scholar
• Khoriaty R, Taher A, Inati A, Lee C. A comparison between prophylaxis and on demand treatment for severe haemophilia. Clin Lab Haematol 2005;27:320-3
   PubMedGoogle Scholar
• van den Berg HM, Fischer K, van der Bom JG. Comparing outcomes of different treatment regimens for severe haemophilia. Haemophilia 2003;9(Suppl 1):27-31
   PubMed Web of Science ®Google Scholar
• Schramm W, Royal S, Kroner B, et al. Clinical outcomes and resource utilization associated with haemophilia care in Europe. Haemophilia 2002;8:33-43
   PubMedGoogle Scholar
• Smith PS, Teutsch SM, Shaffer PA, et al. Episodic versus prophylactic infusions for hemophilia A: a cost-effectiveness analysis. J Pediatr 1996;129:424-31
   PubMed Web of Science ®Google Scholar
• Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007;357:535-44
   PubMed Web of Science ®Google Scholar
• Roosendaal G, Lafeber F. Prophylactic treatment for prevention of joint disease in hemophilia–cost versus benefit. N Engl J Med 2007;357:603-5
   PubMed Web of Science ®Google Scholar
• Gouw SC, van der Bom JG, van den BMHM. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 2007;109:4648-54
   PubMed Web of Science ®Google Scholar
• Morado M, Villar A, Jiménez Yuste V, et al. Prophylactic treatment effects on inhibitor risk: experience in one centre. Haemophilia 2005;11:79-83
   PubMed Web of Science ®Google Scholar
• Berntorp E, Boulyjenkov V, Brettler D, et al. Modern treatment of haemophilia. Bull World Health Organ 1995;73:691-701
   PubMed Web of Science ®Google Scholar
• Medical and Scientific Advisory Council (MASAC). Recommendation Concerning Prophylaxis (Regular Administration of Clotting Factor Concentrate to Prevent Bleeding). Document #179 (Replaces #170) ed. National Hemophilia Foundation, 2007. Available from: http://www.hemophilia.org/NHFWeb/MainPgs/MainNHF.aspx?menuid=57&;contentid=1007
   Google Scholar
• Ewenstein BM, Collins P, Tarantino MD, et al. Hemophilia therapy innovation: development of an advanced category recombinant factor VIII by a plasma/albumin-free method. Proceedings of a Special Symposium at the XIXth Congress of the International Society on Thrombosis and Haemostasis, July 12-18, 2003, Birmingham, UK. Semin Hematol 2004;41:1-16
   PubMedGoogle Scholar
• Shapiro AD. Anti-hemophilic factor (recombinant), plasma/albumin-free method (octocog-alpha; ADVATE) in the management of hemophilia A. Vasc Health Risk Manag 2007;3:1-11
   PubMedGoogle Scholar
• Tarantino MD, Collins PW, Hay CR, et al. Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A. Haemophilia 2004;10:428-37
   PubMed Web of Science ®Google Scholar
• Blanchette VS, Shapiro AD, Liesner RJ, et al. Plasma and albumin free recombinant factor VIII (rAHF-PFM): pharmacokinetics, efficacy and safety in previously treated pediatric patients. J Thromb Haemost 2008;6:1319-26
   PubMed Web of Science ®Google Scholar
• Morfini M, Lee M, Messori A. The design and analysis of half-life and recovery studies for factor VIII and factor IX. Factor VIII/Factor IX Scientific and Standardization Committee of the International Society for Thrombosis and Haemostasis. Thromb Haemost 1991;66:384-6
   PubMed Web of Science ®Google Scholar
• Négrier C, Shapiro A, Berntorp E, et al. Surgical evaluation of a recombinant Factor VIII prepared using a plasma/albumin-free method: Efficacy and safety of Advate in previously treated patients. Thromb Haemost 2008;100:217-23
   PubMed Web of Science ®Google Scholar
• Tarantino MD, Collins PW, Hay PW, et al. Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A. Haemophilia 2004;10:428-37
   PubMed Web of Science ®Google Scholar
• Liesner RJ, Khair K, Hann IM. The impact of prophylactic treatment on children with severe haemophilia. Br J Haematol 1996;92:973-8
   PubMed Web of Science ®Google Scholar
• Manco-Johnson MJ, Nuss R, Geraghty S, et al. Results of secondary prophylaxis in children with severe hemophilia. Am J Hematol 1994;47:113-7
   PubMed Web of Science ®Google Scholar
• Nilsson IM, Berntorp E, Löfqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992;232:25-32
   PubMed Web of Science ®Google Scholar
• Petrini P, Lindvall N, Egberg N, Blombäck M. Prophylaxis with factor concentrates in preventing hemophilic arthropathy. Am J Pediatr Hematol Oncol 1991;13:280-7
   PubMedGoogle Scholar
• Blanchette VS, Shapiro AD, Liesner RJ, et al. Plasma and albumin free recombinant factor VIII (rAHF-PFM): pharmacokinetics, efficacy and safety in previously treated pediatric patients. J Thromb Haemost 2008;6:1319-26
   PubMed Web of Science ®Google Scholar
• Verbruggen B, Novakova I, Wessels H, et al. The Nijmegen modification of the Bethesda assay for Factor VIII: C inhibitors: improved specificity and reliability. Thromb Haemost 1995;73:247-51
   PubMed Web of Science ®Google Scholar
• Björkman S. Prophylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspective. Haemophilia 2003;9(Suppl 1):101-8
   PubMed Web of Science ®Google Scholar
• Carlsson M, Berntorp E, Björkman S, et al. Improved cost-effectiveness by pharmacokinetic dosing of factor VIII in prophylactic treatment of haemophilia A. Haemophilia 1997;3:96-101
   PubMed Web of Science ®Google Scholar
• Efficacy of antihemophilic factor (recombinant), plasma/albumin-free method (rAHF PFM) in bleed treatment. B Ewenstein, L Patrone, P Schroth, K Casey, S Fritsch, B Pavlova, H Ehrlich; Baxter BioScience, Westlake Village, CA and Vienna, Austria. Poster presented at XXI ISTH Congress. July 6-12, 2006; Geneva, Switzerland
   Google Scholar
• Efficacy of antihemophilic factor (recombinant), plasma/albumin-free method (rAHF PFM) in bleed prevention. B Ewenstein, L Patrone, P Schroth, G Spotts, S Fritsch, B Pavlova, H Ehrlich; Baxter BioScience, Westlake Village, CA and Vienna, Austria. Poster presented at XXI ISTH Congress. July 6-12, 2006; Geneva, Switzerland
   Google Scholar
• Konkle BA, Ebbesen LS, Erhardtsen E, et al. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost 2007;5:1904-13
   PubMed Web of Science ®Google Scholar
• Lorenzo JI, Lopez A, Altisent C, Aznar JA. Incidence of factor VIII inhibitors in severe haemophilia: the importance of patient age. Br J Haematol 2001;113:600-3
   PubMed Web of Science ®Google Scholar
• Chalmers EA, Brown SA, Keeling D, et al. Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A. Haemophilia 2007;13:149-55
   PubMed Web of Science ®Google Scholar
• Oldenburg J, El Maarri O, Schwaab R. Inhibitor development in correlation to factor VIII genotypes. Haemophilia 2002;8(Suppl 2):23-9
   PubMed Web of Science ®Google Scholar
• Astermark J, Oldenburg J, Pavlova A, et al. Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A. Blood 2006;107:3167-72
   PubMed Web of Science ®Google Scholar
• Astermark J, Oldenburg J, Carlson J, et al. Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A. Blood 2006;108:3739-45
   PubMed Web of Science ®Google Scholar
• Santagostino E, Mancuso ME, Rocino A, et al. Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study. Br J Haematol 2005;130:422-7
   PubMed Web of Science ®Google Scholar
• Ehrlich HJ, Bray GL, Gomperts ED. Comparison of high responder inhibitor frequency in recent studies of previously untreated patients with hemophilia A. Thromb Haemost 1998;79:242-3
   PubMed Web of Science ®Google Scholar
• Kreuz W, Ettingshausen CE, Zyschka A, et al. Inhibitor development in previously untreated patients with hemophilia A: a prospective long-term follow-up comparing plasma-derived and recombinant products. Semin Thromb Hemost 2002;28:285-90
   PubMed Web of Science ®Google Scholar
• Hay CR. Factor VIII inhibitors in mild and moderate-severity haemophilia A. Haemophilia 1998;4:558-63
   PubMed Web of Science ®Google Scholar
• Luu H, Kriukov A, Stephens D, et al. The safety and efficacy of ADVATE [Antihemophilic Factor (recombinate), Plasma/Albumin-Free Method (rAHF-PFM)] in routine clinical practice: Results from post-authorization safety surveillance (PASS) in PUPs and PTPs following product switch. Poster presented at 50th Annual Meeting of the American Society of Hematology. December 6-9, 2008; San Francisco, CA
   Google Scholar
• Abshire TC, Brackmann HH, Scharrer I, et al. Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy–International Kogenate-FS Study Group. Thromb Haemost 2000;83:811-6
   PubMed Web of Science ®Google Scholar
• Courter SG, Bedrosian CL. Clinical evaluation of B-domain deleted recombinant factor VIII in previously treated patients. Semin Hematol 2001;38:44-51
   PubMed Web of Science ®Google Scholar
• Schwartz RS, Abildgaard CF, Aledort LM, et al. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. Recombinant Factor VIII Study Group. N Engl J Med 1990;323:1800-5
   PubMed Web of Science ®Google Scholar
• White GC, Courter S, Bray GL, et al. A multicenter study of recombinant factor VIII (Recombinate) in previously treated patients with hemophilia A. The Recombinate Previously Treated Patient Study Group. Thromb Haemost 1997;77:660-7
   PubMed Web of Science ®Google Scholar
• Yoshioka A, Shima M, Fukutake K, et al. Safety and efficacy of a new recombinant FVIII formulated with sucrose (rFVIII-FS) in patients with haemophilia A: a long-term, multicentre clinical study in Japan. Haemophilia 2001;7:242-9
   PubMed Web of Science ®Google Scholar
• Barnes C, Lillicrap D, Pazmino-Canizares J, et al. Pharmacokinetics of recombinant factor VIII (Kogenate-FS) in children and causes of inter-patient pharmacokinetic variability. Haemophilia 2006;12:40-9
   Web of Science ®Google Scholar
• Kelly KM, Butler RB, Farace L, et al. Superior in vivo response of recombinant factor VIII concentrate in children with hemophilia A. J Pediatr 1997;130:537-40
   PubMed Web of Science ®Google Scholar
• Matucci M, Messori A, Donati-Cori G, et al. Kinetic evaluation of four factor VIII concentrates by model-independent methods. Scand J Haematol 1985;34:22-8
   PubMedGoogle Scholar
• DiMichele DM. Management of factor VIII inhibitors. Int J Hematol 2006;83:119-25
   PubMed Web of Science ®Google Scholar
• Shapiro AD, Korth-Bradley J, Poon MC. Use of pharmacokinetics in the coagulation factor treatment of patients with haemophilia. Haemophilia 2005;11:571-82
   PubMed Web of Science ®Google Scholar
• Berntorp E, Björkman S. The pharmacokinetics of clotting factor therapy. Haemophilia 2003;9:353-9
   PubMed Web of Science ®Google Scholar
• Lee M, Morfini M, Négrier C, Chamouard V. The pharmacokinetics of coagulation factors. Haemophilia 2006;12(Suppl 3):1-7
   PubMed Web of Science ®Google Scholar
• Morfini M, Cinotti S, Bellatreccia A, et al. A multicenter pharmacokinetic study of the B-domain deleted recombinant factor VIII concentrate using different assays and standards. J Thromb Haemost 2003;1:2283-9
   PubMed Web of Science ®Google Scholar
• Lusher JM, Lee CA, Kessler CM, Bedrosian CL. The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A. Haemophilia 2003;9:38-49
   PubMed Web of Science ®Google Scholar
• Roosendaal G, Lafeber FP. Pathogenesis of haemophilic arthropathy. Haemophilia 2006;12(Suppl 3):117-21
   PubMed Web of Science ®Google Scholar
• Goddard NJ, Mann H. Diagnosis of haemophilic synovitis. Haemophilia 2007;13(Suppl 3):14-9
   PubMed Web of Science ®Google Scholar
• Luck JV Jr, Silva M, Rodriguez-Merchan EC, et al. Hemophilic arthropathy. J Am Acad Orthop Surg 2004;12:234-45
   PubMed Web of Science ®Google Scholar
• Gilbert MS, Radomisli TE. Therapeutic options in the management of hemophilic synovitis. Clin Orthop Relat Res 1997;343:88-92
   PubMed Web of Science ®Google Scholar
• Wallny T, Lahaye L, Brackmann HH, et al. Clinical and radiographic scores in haemophilic arthropathies: how well do these correlate to subjective pain status and daily activities? Haemophilia 2002;8:802-8
   PubMed Web of Science ®Google Scholar
• van Genderen FR, Fischer K, Heijnen L, et al. Pain and functional limitations in patients with severe haemophilia. Haemophilia 2006;12:147-53
   PubMed Web of Science ®Google Scholar
• Choiniére M, Melzack R. Acute and chronic pain in hemophilia. Pain 1987;31:317-31
   PubMed Web of Science ®Google Scholar
• Pollmann H, Externest D, Ganser A, et al. Efficacy, safety and tolerability of recombinant factor VIII (REFACTO) in patients with haemophilia A: interim data from a postmarketing surveillance study in Germany and Austria. Haemophilia 2007;13:131-43
   PubMed Web of Science ®Google Scholar
• Khoriaty R, Taher A, Inati A, Lee C. A comparison between prophylaxis and on demand treatment for severe haemophilia. Clin Lab Haematol 2005;27:320-3
   PubMedGoogle Scholar
• Janco RL, Maclean WE, Perrin JM, Gortmaker SL. A prospective study of patterns of bleeding in boys with haemophilia. Haemophilia 1996;2:202-6
   Web of Science ®Google Scholar
• White GC II, Courter S, Bray GL, et al. A multicenter study of recombinant factor VIII (Recombinate) in previously treated patients with hemophilia A. Thromb Haemost 1997;77:660-7
   PubMed Web of Science ®Google Scholar
• Pollmann H, Richter H, Ringkamp H, Jürgens H. When are children diagnosed as having severe haemophilia and when do they start to bleed? A 10-year single-centre PUP study. Eur J Pediatr 1999;158(Suppl 3):S166-70
   PubMed Web of Science ®Google Scholar
• van Dijk K, Fischer K, van der Bom JG, et al. Variability in clinical phenotype of severe haemophilia: the role of the first joint bleed. Haemophilia 2005;11:438-43
   PubMed Web of Science ®Google Scholar
• Onwuzurike N, Warrier I, Lusher JM. Types of bleeding seen during the first 30 months of life in children with severe haemophilia A and B. Haemophilia 1996;2:137-40
   Web of Science ®Google Scholar
• Royal S, Schramm W, Berntorp E, et al. Quality-of-life differences between prophylactic and on-demand factor replacement therapy in European haemophilia patients. Haemophilia 2002;8:44-50
   PubMed Web of Science ®Google Scholar
• Fischer K, van der Bom JG, Mauser-Bunschoten EP, et al. Changes in treatment strategies for severe haemophilia over the last 3 decades: effects on clotting factor consumption and arthropathy. Haemophilia 2001;7:446-52
   PubMed Web of Science ®Google Scholar
• Fischer K, van der Bom JG, Molho P, et al. Prophylactic versus on-demand treatment strategies for severe haemophilia: a comparison of costs and long-term outcome. Haemophilia 2002;8:745-52
   PubMed Web of Science ®Google Scholar
• Hacker MR, Geraghty S, Manco-Johnson M. Barriers to compliance with prophylaxis therapy in haemophilia. Haemophilia 2001;7:392-6
   PubMed Web of Science ®Google Scholar
• La Greca AM. Issues in adherence with pediatric regimens. J Pediatr Psychol 1990;15:423-36
   PubMed Web of Science ®Google Scholar
• Kyngas H. Compliance of adolescents with chronic disease. J Clin Nurs 2000;9:549-56
   PubMed Web of Science ®Google Scholar
• World Health Organization. Adherence to long-term therapies project report. In: Sabate E, editor, A Global Initiative Launched in 2001 by the Non-communicable Diseases and Mental Health Cluster of the World Health Organization.Geneva, Switzerland: World Health Organization, 2003. p. 22
   Google Scholar
• du Treil S, Rice J, Leissinger CA. Quantifying adherence to treatment and its relationship to quality of life in a well-characterized haemophilia population. Haemophilia 2007;13:493-501
   PubMed Web of Science ®Google Scholar